The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study

Conditions

• Cardiac Magnetic Resonance Imaging
• Ischemic Heart Disease (IHD)
• Myocardial Blood Flow

Eligibility Criteria

Sex

ALL

Age

35 Years - 85 Years

Healthy Volunteers

Not accepted

Interventions

• Quantitative Myocardial Blood Flow Evaluation — DIAGNOSTIC_TEST
  The perfusion sequence will produce on-the-fly additional quantitative perfusion maps with segmental myocardial blood flow values.
• Qualitative Myocardial Blood Flow Evaluation — DIAGNOSTIC_TEST
  The perfusion sequence will not produce additional quantitative perfusion maps.
• Gadavist — DRUG
  Participants will receive Gadavist 0.05 mmol/kg dose for each stress and rest perfusion imaging (total dose of 0.1 mmol/kg).
• Vasodilator — DRUG
  All participants will receive vasodilator (regadenoson or adenosine depending on local site practice).
• Blood draw for the laboratory assessment — DIAGNOSTIC_TEST
  A single (7-10 ml tube) whole blood sample will be collected from each patient for processing of blood biomarkers.

Study Details

This research aims to investigate whether symptoms of chest pain or shortness of breath among the study population are arising due to a heart problem, particularly any reduction of blood flow to the heart muscle from blockages in the coronary blood vessels or inflammation of the heart using cardiac magnetic resonance imaging that measures the amount of blood flow during a stress state meant to simulate vigorous exercise. At present, doctors use standard magnetic resonance imaging pictures of blood flow patterns to treat heart disease. The investigators want to study if detailed blood flow measurements, in addition to the standard blood flow pattern, could diagnose heart disease more accurately and allow more doctors to understand the severity of heart disease. Early research has demonstrated that detailed blood flow measurements may be more accurate in diagnosing heart disease in some patients, but doctors need more information to know how to use these measurements.

Key Dates

Start date

Jun 27, 2025

Status verified

Feb 2026

Primary completion

Jan 31, 2029

Completion

Mar 31, 2029

Study Design

Enrollment

1,000 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Arms

• Active Comparator: Standard Myocardial Blood Flow Evaluation
  Qualitative stress cardiac magnetic resonance imaging only.
• Experimental: New Myocardial Blood Flow Evaluation
  Quantitative + Qualitative stress cardiac magnetic resonance imaging.

Primary Outcome Measure

Primary composite outcome of major cardiovascular adverse events (MACE) [ Time Frame: From cardiac magnetic resonance imaging to the end of follow-up in 24 months ]

Central Contacts

• Raymond Y Kwong, MD, MPH
  857-307-1960
  [email protected]
• Bobby Heydari, MD, MPH
  [email protected]

Locations (12)

Find similar trials in San Francisco, CA

Related Studies

• Prognostic Value of Hyperpolarized 13C MRI for Clinical Myocardial Viability
  Recruiting · University of Texas Southwestern Medical Center · Dallas, Texas
• Acolyte CTO-PCI Study: Imaging and Catheter System to Treat Patients With Coronary Chronic Total Occlusion, Who Have Persistent Symptoms Following Medical Therapy and Are Undergoing Percutaneous Coronary Interventional Procedures
  Enrolling By Invitation · Elumn8 Medical · Atlanta, Georgia